

## INDEX

*Note:* Page numbers in *italics* indicate figures; page numbers followed by t refer to tables.

### Ablation

- hormone. See *Hormone ablation*.
- laser, x, 57, 99-100, 101, 102, 143
- transurethral needle, of prostate, 102

### Abscess, prostatic

- ampicillin for, 35
- antimicrobials for, 35
- catheterizations and, 35
- conditions predisposing to, 35
- in diabetes mellitus, 35
- diagnosis of, 26
- incision and drainage of, 35
- transurethral resection for, 36

### Aconitic acid, 46

### $\alpha$ -Adrenergic receptor blockers. See also specific drug, eg,

#### *Terazosin*.

- for BPH, ix, 57, 66t, 144
- prostate-specific, ix
- for prostatitis, 37

#### 5 $\alpha$ -reductase inhibitor with, 95

### $\alpha$ -Adrenergic receptors, in prostate, 63-64

### $\beta$ -Adrenergic receptors, in prostate, 63

### $\alpha$ -Adrenergic tone, of capsular smooth muscle, TUMT

- effect on, 98

### Adriamycin, 137

### African American men, prostate cancer in, 107

### African plum, 59

- action mechanism of, 62-63
- on CAMUS trial, 63
- effectiveness of, 63
- scientific name of, 62t

### Age/aging

- BPH and, 39, 40
- intravenous therapy and, 34
- prostate cancer and, 109
- prostate disease and, ix
- PSA and, 115-116
- urinary flow rate and, 50

### $\alpha$ -Agonist decongestants, 48

### Alcohol consumption, 48

### Alfuzosin (Uroxatral)

- action mechanism of, 67t, 78
- dosage of, 67t, 82
- IPSS after, 79, 80-81
- pharmacokinetics of, 78-79
- side effects of, 67t, 82
- urine flow rate after, 79, 80-81

### American Joint Cancer Committee TNM staging system, 119, 120t-122t

### American Urological Association (AUA) Symptom Index, 47, 54, 58, 60t-61t. See also specific drug.

### Aminoglutethimide

- action mechanism of, 129, 131, 134
- dosage of, 130t, 134
- in hormone ablation, 129, 130t, 131, 134
- side effects of, 130t, 134-135

### Aminoglycoside, 34

### Ampicillin

- for acute bacterial prostatitis, 34, 139
- intravenous, 35, 139
- for prostatic abscess, 35

### Androgen ablation. See also *Hormone ablation*.

- approaches to, 131
- sites of, 130t

### Anti-inflammatory agents, 36-37, 63, 116

### Antiandrogen agents. See also 5 $\alpha$ -Reductase inhibitors.

- action mechanism of, 133
- disadvantages of, 134
- dosage of, 130t, 134
- LHRH analogue with
  - action mechanism of, 129
  - for androgen ablation, ix, 129, 130t, 133, 135t, 148-149
  - side effects of, 135t
- nonsteroidal, 132, 134
- side effects of, 130t, 134, 135t

### Anticholinergic agents, for CPPS, 37

### Antidepressants, urinary retention and, 48

### Antimicrobial agents. See also specific agent, eg,

#### *Tetracycline*.

- for CPPS
  - inflammatory, 17t
  - noninflammatory, 17t, 37
- diffusion of, 33
- intravenous, 34-35

- Antimicrobial agents (*continued*)  
 for prostatic abscess, 35  
 for prostatitis, 17t  
   acute bacterial, 34  
   chronic bacterial, 33, 35-36  
 VB<sub>2</sub> count and, 31
- Avodart. See *Dutasteride*.
- Avolve. See *Dutasteride*.
- Azotemia, 104
- Back pain, in CPPS, 19
- Bacteremia, 26
- Bacterial prostatitis. See *Prostatitis, acute bacterial; Prostatitis, chronic bacterial*.
- Benign prostatic hyperplasia (BPH)  
 age/aging and, 39, 40  
 anatomy of, 42  
 causes of, 39, 106  
 diagnosis of, 47  
   American Urological Association symptom index for, 47, 54, 58, 60t-61t  
   cystoscopy in, 51  
   flow chart for, 54-55, 143  
   laboratory examination in, 50, 143  
   physical examination in, 48-49, 142, 144  
   prostatic acid phosphatase in, 114, 143  
   radiologic, 52, 53  
   rectal examination in, 48-49, 142, 144-145  
   symptoms in, 47-48, 142, 144  
   urodynamics in, 50-51, 145  
   uroflow in, 50  
 incidence of, x, 39  
 pathophysiology of, 39, 41, 42-43  
 progression of, 39, 145  
 prostate cancer and, 108-109  
 recurrent, 106  
 serum compounds in, 46  
 sites of, 43  
 staged bladder response to, 41, 44  
 testosterone and, 44, 45, 46  
 treatment of  
   flow chart for, 54-55  
   herbal, 62t  
   laser ablation in, x, 57, 99-100, 101, 102, 143  
   lifestyle changes in, 58, 142, 144
- Benign prostatic hyperplasia, treatment of (*continued*)  
 microwave hyperthermia in. See *Transurethral microwave thermotherapy*.  
 pharmacologic, ix, 57, 63, 66t-67t. See also specific drugs.  
 phytotherapeutic, ix, 62t  
 stents in, 57, 97-98  
 surgical, x, 100, 104-106, 105, 144  
 transurethral incision in, 144  
 ultrasound in, 57  
 urethral obstruction from, 41, 42
- Bicalutamide  
 action mechanism of, 131  
 dosage of, 1346  
 LHRH analogue-induced testosterone flare and, 132  
 PSA and, 137  
 side effects of, 134, 135t
- Biofeedback, 37
- Biopsy, transrectal ultrasound-guided, x, 116-117
- Bladder. See also *Urinary* entries.  
 in BPH, 41, 44, 47-48  
 calculi in, 48, 51  
   surgery for, 104  
 distended, 26  
 diverticula of, 51  
 intravenous pyelograph of, 47-48, 49  
 irritability of  
   causes of, 51  
   urinary frequency in, 41, 47-48  
 neoplasms of, 48  
 normal capacity of, 43  
 obstruction of, 51  
   castration and, 44  
 tumors in, 51  
 in urodynamic testing, 50-51, 145  
 voided, 26, 30
- Bladder neck  
 contracture of, 48, 106, 125  
 during ejaculation, 11  
 obstruction of, 99  
 spasms of, 21  
 strictures of, 102
- Bleeding, prostatic, 106
- Blood, in urine, 104
- Blood vessels, of prostate, 11, 13, 14

- Bone, prostate cancer metastasis to, 122t
- Bone cancer, 113
- BPH. See Benign prostatic hyperplasia.
- Brachytherapy
  - indications for, 146, 147
  - for prostate cancer, 127
  - transperineal, for prostate cancer, ix
- Breast cancer, 133
- Cadmium, 42
  - prostate cancer and, 108
- Caffeine, 33
  - in inflammatory CPPS, 36
- Calculi
  - in bladder, 48, 51, 104
  - surgery for, 58, 104
  - causes of, 33
  - in prostate, 33, 36, 142
  - rectal examination distortion by, 113
- CAMUS (Complementary and Alternative Medicine for Urinary Symptoms) trial, 63
- Cancer
  - of bone, 113
  - of breast, 133
  - endometrial, 133
  - of prostate. See *Prostate cancer*.
- Carbenicillin, 36, 141
- Cardura. See *Doxazosin*.
- Castration
  - prostate cancer and, 108, 128-129, 131, 149
  - urinary obstruction and, 44
- Catheterization
  - bacterial prostatitis from, 15, 34, 145
  - catheter placement in, 35
  - contraindications for, 139
  - prostatic abscess and, 35
  - for urinary retention, 35
- Caucasian men, prostate cancer in, 107
- Ceftriaxone sodium, 141
- Cephalosporin, 34
- Chemotherapy, for prostate cancer, 137
- Chlamydia*, asymptomatic inflammatory prostatitis from, 17t
- Chlamydia* infection
  - doxycycline for, 141
  - inflammatory CPPS from, 17t
- Cholesterol
  - doxazosin mesylate and, 70
  - terazosin and, 64
- Chronic pelvic pain syndrome
  - causes of pain in, 19
  - site of pain in, 19
- Chronic pelvic pain syndrome, inflammatory (formerly nonbacterial prostatitis), x, 15, 20
  - causes of, 17t
  - clinical features of, 17t
  - diagnosis of, 17t
  - microscopic findings in, 28t
  - NIH description of, 16t
  - treatment of, 17t, 36-37
- Chronic pelvic pain syndrome, noninflammatory (formerly prostatodynia), x, 15
  - causes of, 17t, 20-21
  - clinical features of, 17t, 20, 141-142
  - diagnosis of, 17t, 23, 26, 141
  - microscopic findings in, 28t
  - NIH description of, 16t
  - treatment of, 17t, 37-38, 141
- Ciprofloxacin
  - ampicillin with, 139
  - for bacterial prostatitis
    - acute, 34, 139
    - chronic, 35, 142
  - for bacterial urethritis, 141
  - for CPPS
    - inflammatory, 141
    - noninflammatory, 37
  - intravenous, 34-35, 139
  - for prostatic abscess, 35
  - before TRUS-guided biopsy, 116
- Cisplatin, 137
- Citric acid, 46
- Coagulation, with laser, ix, 99, 101
- Colic, renal, 26
- Coliform bacteria, in bacterial prostatitis, 17t
- Complementary and Alternative Medicine for Urinary Symptoms (CAMUS) trial, 63
- Constipation, 21
- CPPS. See *Chronic pelvic pain syndrome* entries.
- Cryosurgery
  - for prostate cancer, 128
  - transperineal, ix

- Curcubita pepo* (pumpkin seeds), 62t  
 Cyclophosphamide, 137  
 Cystitis  
   causes of, 26, 127  
   interstitial  
     inflammatory CPPS from, 20  
     noninflammatory CPPS from, 21  
   microscopic findings in, 28t  
 Cystoscopy  
   acute bacterial prostatitis from, 15  
   in BPH, 51
- Dacarbazine, 137  
 Decongestants,  $\alpha$ -agonist, 48  
 DES (diethylstilbestrol)  
   for hormone ablation, 129, 132  
   palliative, 137  
 Detrusor muscle hypertrophy, 51  
 DHT. See *Dihydrotestosterone*.  
 Diabetes mellitus  
   acute bacterial prostatitis in, 139, 141  
   prostate abscess in, 35  
   urinary hesitancy in, 48  
 Diazepam, 37, 142  
 Diet  
   in inflammatory CPPS, 36  
   prostate cancer and, 108  
 Diethylstilbestrol  
   for hormone ablation, 129, 132  
   palliative, 137  
 Dihydrotestosterone  
   in BPH, 44, 45, 46, 67t  
   dutasteride effect on, 83, 87, 90, 90  
   finasteride effect on, 83, 90, 90  
   in hormone ablation, 131  
   LHRH analogues and, 132  
   5 $\alpha$ -reductase inhibitors and, 67t, 82-83  
   saw palmetto effect on, 59  
 Diuretics  
   in BPH, 58  
   urinary retention caused by, 48  
 Diverticula of bladder, 51, 58  
 Docetaxel, 137
- Doxazosin (Cardura)  
   action mechanism of, 66t  
   for BPH, 57, 64, 66t, 70-71  
   dosage of, 66t, 71  
   effectiveness of, 66t, 70-71, 72, 73  
   in MTOPS trial, 96  
   symptom score after, 72  
   tamsulosin vs, 73  
   urinary flow after, 72  
   cholesterol and, 70  
   for noninflammatory CPPS, 37  
   pharmacokinetics of, 66t, 70  
   side effects of, 66t, 71  
   structure of, 65
- Doxycycline  
   for chronic bacterial prostatitis, 36  
   for gonorrhea or chlamydial infection, 141  
   for inflammatory CPPS, 36, 140
- Dutasteride (Avodart, Avolve)  
   action mechanism of, 67t, 87  
   AUA symptom index after, 91-92, 93  
   AUA symptom score and urinary flow after, 93  
   dihydrotestosterone concentration and, finasteride vs,  
     90, 90  
   dihydrotestosterone concentration and, 87, 90  
   dosage of, 67t, 87, 94-95  
   molecular structure of, 65  
   prostate volume after, 67t, 91, 94  
   PSA after, 97  
   side effects of, 67t, 93-94  
   urinary flow rate after, 91-92, 93
- Dwarf palm, 62t  
 Dysuria, 127
- Echinacea purpurea* (purple cone flower), 62t  
 Edema, in leg, 113  
 Ejaculation  
   prostate during, 11  
   retrograde, 11  
   tamsulosin effects on, 76-77  
 Elderly patient. See *Age/aging*.  
 Emotional instability, in CPPS, 21  
 Emotional support, 37-38  
 Endometrial cancer, 133  
 Enema, 116

- Environmental toxins, prostate cancer and, 108
- Epididymitis, 26, 27
- EPS. See *Expressed prostatic secretions*.
- Erectile dysfunction, 106, 127
- Erythromycin
  - for chronic bacterial prostatitis, 36
  - for inflammatory CPPS, 36
- Estramustine, 137
- Estrogen(s)
  - aminoglutethimide and, 134
  - for hormone ablation, 129, 130t, 133
    - action mechanism of, 129, 131
    - dosage of, 129, 130t
    - side effects of, 129, 130t, 132
  - from plant extracts, 62
  - saw palmetto and, 59
- Ethinyl estradiol, 129
- Expressed prostatic secretions (EPS)
  - in asymptomatic inflammatory prostatitis, 16t
  - in bacterial prostatitis
    - acute, 33
    - chronic, 19, 33
  - categories of, 26, 28t, 30-31
  - collection of, 29, 30
  - in inflammatory CPPS, 16t
  - to localize infection, 31, 32
  - microscopic examination of, 26, 28t, 30-31
  - in noninflammatory CPPS, 16t, 20, 141-142
- External beam radiation, ix, 126-127, 137, 148
  - cryosurgery after, 128
  - PSA and, 126
- Fatty acids
  - from plant extracts, 62t
  - in prostate cancer etiology, 108
- Finasteride (Proscar). See also *Proscar Long-Term Efficacy and Safety Study (PLESS)*.
  - action mechanism of, 67t, 83, 87
  - advantages of, 83
  - AUA symptom score after, 84, 84
  - for BPH, 57, 67t, 83-86, 144
  - dihydrotestosterone concentration and, 90, 90
  - dosage of, 67t, 84, 87
  - effectiveness of, 67t, 83-86
  - molecular structure of, 65
- Finasteride (*continued*)
  - on MTOPS trial, 96
  - pharmacokinetics of, 67t, 83
  - prostate cancer and, 86
  - in Prostate Cancer Prevention Trial, 86, 88-89
  - prostate volume after, 84-85, 85
  - prostate volume before, 86
  - PSA screening and, 86, 97
  - saw palmetto vs, 59
  - side effects of, 67t, 83, 85-86
  - terazosin vs, 69
  - urinary flow rate after, 83
- Fissure
  - rectal, 26
  - renal, 26
- Flank pain, 26
- Flavonoids, from plant extracts, 62t
- Fleet enema, 116
- Flomax. See *Tamsulosin*.
- Fluoroquinolone, 34
- Fluorouracil, 137
- Flutamide
  - action mechanism of, 131
  - dosage of, 130t, 134
  - indications for, 146
  - LHRH analogue-induced testosterone flare and, 132
  - LHRH analogue with, 134, 135t
  - PSA and, 137
  - side effects of, 130t, 134, 135t
- Foley catheterization. See *Catheterization*.
- Genetics of prostate cancer, 108
- Gentamicin
  - for acute bacterial prostatitis, 34, 139
  - for prostatic abscess, 35
- Gleason Scale, 117, 118
- Glucocorticoids
  - aminoglutethimide effect on, 134
  - in hormone ablation, 130t
- Gonorrhea, 141
- Goserelin (Zoladex)
  - dosage of, 132
  - indications for, 146, 148
  - side effects of, 133
- Gram-positive bacteria, spermatozoa activity against, 14

- Groin pain, in CPPS, 19
- Heavy metal exposure, 108
- Hematuria, 104
- Hemorrhoids
  - noninflammatory CPPS from, 21
  - prostatitis and, 26
- Herbal therapy, for BPH, 58
- Hipoxis rooperi* (South African star grass), 62t
- Histology, in prostate cancer grading, 117, 118
- HIV (human immunodeficiency virus) infection, 35
- Hormone ablation. See also *Laser ablation*.
  - action sites in, 131
  - aminoglutethimide in, 129, 130t, 131, 134
  - antiandrogens in, 130t, 133-134
  - diethylstilbestrol in, 129, 130t, 132
  - dihydrotestosterone in, 131
  - effectiveness of, 129
  - estrogens in, 129, 130t, 132
  - glucocorticoids in, 130t
  - in hormone-refractory disease, 137
  - immediate vs deferred, 136
  - ketoconazole in. See *Ketoconazole*.
  - LHRH analogues in, 129, 130t, 132-133
  - LHRH analogues plus antiandrogens in, ix, 129, 130t, 133, 135t, 148-149
  - pharmacologic, ix
  - for prostate cancer, 128-129, 130t, 132-136
    - as intermittent therapy, 136-137
  - rationale for, 128
- Hospitalization
  - for acute bacterial prostatitis, 35
  - for prostatitis, 34
- Human immunodeficiency virus (HIV) infection, 35
- Hydronephrosis, 58
- Hyperplasia, benign prostatic. See *Benign prostatic hyperplasia*.
- Hypertension
  - doxazosin mesylate for, 70
  - terazosin for, 64, 69-70
- Hyperthermia, microwave. See *Transurethral microwave thermotherapy*.
- Hyponatremia, 105
- Hytrin. See *Terazosin*.
- Ibuprofen, 37
- Immune response
  - noninflammatory CPPS and, 21
  - prostatic, 14
- Immunocompromised patient
  - acute bacterial prostatitis in, 34
  - prostatic abscess in, 35
- Immunoglobulin G/immunoglobulin A, prostatic, 14
- Impotence, 106, 127
- Incision, prostatic. See *Transurethral incision of prostate*.
- Incontinence, stress, 106
- Indomethacin, 37
- Infection
  - HIV, 35
  - prostate cancer and, 108
  - prostate resistance to, 14
- Infertility, asymptomatic inflammatory prostatitis and, 21, 38
- International Prostate Symptom Score (IPSS)
  - alfuzosin and, 79, 80-81
  - combination therapy and, 95
- Interstitial cystitis
  - inflammatory CPPS from, 20
  - noninflammatory CPPS from, 21
- Intravenous pyelography, 52, 53
- Intravenous therapy
  - for acute bacterial prostatitis, 34
  - age/aging and, 34
- Iodine-125, implanted, 127
- Ketoconazole
  - action mechanism of, 129, 131, 135-136
  - alfuzosin with, 78
  - disadvantages of, 136
  - dosage of, 130t, 135-136
  - LHRH analogue-induced testosterone flare and, 132, 148
  - palliative, 137
  - pharmacokinetics of, 136
  - side effects of, 130t, 136
- Lactate dehydrogenase, in prostatic fluid, 28t
- Lactic acid, 46
- Laser ablation, for BPH, x, 57, 99-100, 101, 102, 143
- Laser prostatectomy, ix, 99-100, 101, 102
  - transurethral prostatectomy vs, 99-100, 102
- Lectins, from plant extracts, 62t

- Leg edema, 113
- Leuprolide (Lupron)
  - dosage of, 132
  - indications for, 148
  - side effects of, 133
- Leuprolide acetate implant (Viadur)
  - dosage of, 132
  - indications for, 148
  - side effects of, 28t
- Levofloxacin
  - ampicillin with, 139
  - for bacterial prostatitis
    - acute, 34, 139, 141
    - chronic, 35, 142
  - for noninflammatory CPPS, 37
  - for prostatic abscess, 35
  - before TRUS-guided biopsy, 116
- LHRH. *See Luteinizing hormone-releasing hormone* entries.
- Lifestyle modification
  - for BPH, 58, 144
  - for noninflammatory CPPS, 38
- Lomustine, 137
- Lupron (leuprolide)
  - dosage of, 132
  - indications for, 148
  - side effects of, 133
- Luteinizing hormone-releasing hormone (LHRH), BPH
  - and, 45
- Luteinizing hormone-releasing hormone (LHRH) analogues
  - contraindications for, 132
  - dosage of, 130t, 132
  - for hormone ablation, 129, 131, 132
  - PSA and, 132
  - side effects of, 133
- Luteinizing hormone-releasing hormone (LHRH) analogues plus antiandrogens, for hormone ablation, ix, 129, 130t, 133, 135t, 148-149
  - action mechanism of, 129
  - side effects of, 135t
- Lymph node(s)
  - pelvic, metastasis to, 113, 121t-122t
  - of prostate, 11, 13, 14
- Lymphadenectomy, in prostate cancer staging, 126
- Magnesium, 46
- Massage
  - prostatic
    - contraindications for, 19, 26
    - technique of, 30
    - urine specimen collection before and after, 31
  - urethral, 26
- Medical history, 23
- Medical Therapy of Prostate Symptoms (MTOPS) trial
  - outcome measures in, 95
  - procedures in, 96
  - results of, 96-97
- Medroxyprogesterone acetate, 134
- Metastasis of prostate cancer
  - in staging, 122t
  - in treatment planning, 147
- Methotrexate, 137
- Microscopic examination, 26, 28t, 29-30, 30-31
- Microwave thermotherapy. *See Transurethral microwave thermotherapy.*
- Mitoxantrone, 137
- MTOPS (Medical Therapy of Prostate Symptoms) trial
  - outcome measures in, 96
  - procedures in, 96
  - results of, 96-97
- National Institutes of Health, Chronic Prostatitis Symptom
  - Index of, 23, 24t-25t
- Needle ablation of prostate, transurethral (TUNA), 102
- Neoplasms, in bladder, 48
- Nettle, stinging, 62t
- Neurologic disease
  - CPPS from, 19
  - urinary hesitancy from, 48
- Neuromuscular dysfunction, 21
- Orchiectomy
  - prostate cancer and, 108, 128-129, 131, 149
  - urinary obstruction and, 44
- Organ Systems Coordinating Center of NCI, prostate cancer staging system of, 119, 120t-122t, 123
- Oxybutynin, 37

Pain. See also *Chronic pelvic pain syndrome* entries.  
 in differential diagnosis, 26  
 in flank, 26  
 management of, 137

Palladium, radioactive, implanted, 127

Palmetto berry, ix, 59

PAP. See *Prostatic acid phosphatase*.

Parasympatholytic agents, 48

Pelvic floor muscle tension, CPPS from, 21

Pelvic lymph nodes, metastatic, 113

Pelvic venous congestion, 21

Penicillin G, 31

Penile pain, in CPPS, 19

Perineum, pain in, 19

Physical examination, 23, 26. See also *Rectal examination*.

Phytoestrogens, 62t

Phytosterols, 58t

Phytotherapy, ix. See also *African plum*; *Saw palmetto*.  
 in CAMUS trial, 63  
 history of, 58-59  
 plant extracts used in, 62t  
 popularity of, 59

Plant extracts. See *African plum*; *Phytotherapy*; *Saw palmetto*.

PLESS (Proscar Long-Term Efficacy and Safety Study)  
 AUA symptom scores on, 84, 84  
 prostate volume changes on, 84, 85

Plum, African, 59, 62t, 62-63

Polysaccharides, from plant extracts, 62t

Potassium-titanyl-phosphate laser, in prostate ablation, x,  
 57, 99-100, 101, 102, 143

Prednisone, 130t, 137  
 dosage of, 130t  
 for hormone-refractory prostate cancer, 137

Premarin, 129

Proctitis, 127

Proscar. See *Finasteride*.

Proscar Long-Term Efficacy and Safety Study (PLESS)  
 AUA symptom scores on, 84, 84  
 prostate volume changes on, 84, 85

ProstaScint imaging, 119

Prostate cancer  
 age and, 109  
 BPH and, 107-109  
 death from, 107-108, 111, 126

Prostate cancer (*continued*)  
 diagnosis of  
 flow chart for, 146  
 histology in, 117, 118  
 PSA level in, ix-x, 113-115, 146, 147-148  
 rectal examination in, 113, 123, 145, 147  
 rectal ultrasound-guided biopsy in, x, 116-117, 128  
 serum markers in, 114-116, 146, 147  
 symptoms in, 113

diet and, 108

etiology of, 108

finasteride and, 86, 88-89

genetic predisposition to, 108

hormone-refractory, 137

incidence of, x, 107-108

location of, 109, 110, 113  
 androgen deprivation and, 131

metastasis of, 122t, 147-148

natural history of, 109, 111

pain relief in, 137

primary tumor in, 121t-122t

race and, 107

staging of, x, 147  
 Gleason system in, 117, 118  
 histology in, 117, 118  
 lymphadenectomy in, 126  
 TNM system in, 119, 120t-122t  
 Whitmore system in, 119, 120t, 122t, 123

treatment of  
 brachytherapy in, ix, 127  
 castration in, 128-129, 131, 149  
 chemotherapy in, 137  
 cryosurgery in, 128  
 hormone ablation in. See *Hormone ablation*.  
 immediate vs deferred, 136  
 intermittent, 136-137  
 metastatic evaluation in, 147  
 palliative, 137  
 radiation therapy in, ix, 126-127, 137, 148  
 radical prostatectomy in, 125-126  
 radioactive implantation in, 127  
 suramin in, 137

Prostate Cancer Prevention Trial, 86, 88-89



- Prostate disease. See also specific disease, eg, *Benign prostatic hyperplasia*.
- age/aging and, ix
- Prostate gland
- α-adrenergic receptors in, 63-64
  - β-adrenergic receptors in, 63
  - anatomic relationships of, 11, 12
  - bleeding from, 106
  - blood vessels of, 11, 13, 14
  - calculi in, 33, 36, 142
  - cancer zones in, 109, 110
    - androgen deprivation and, 131
  - components of, 11
  - during ejaculation, 11
  - enlarged/inflamed. See also *Benign prostatic hyperplasia*.
    - diagnosis of, 26
    - urethral obstruction by, 11, 33, 41, 42
  - growth of, 39, 40, 49. See also *Benign prostatic hyperplasia*.
  - incision in. See *Transurethral incision of prostate*.
  - infection resistance in, 14
  - laser ablation of, for BPH, x, 57, 99-100, 101, 102, 143
  - lymphatics of, 11, 13, 14
  - obstruction of, 36
    - causes of, 39
  - palpation of, 49
  - resection of. See *Transurethral resection of prostate*.
  - resistance to infection, 14
  - stenting of, 57, 97-98
  - testosterone and, 44, 45, 46
  - urethral obstruction by, 11, 33, 41, 42
  - vaporization of, 103-104
  - volume of
    - dutasteride and, 67t, 91, 94
    - finasteride and, 67t, 84-85, 85
    - on PLESS, 84, 85
- Prostate massage
- contraindications for, 18-19, 26
  - technique of, 30
  - urine specimen collection before and after, 31
- Prostate resection, transurethral. See *Transurethral resection of prostate*.
- Prostate secretions, expressed. See *Expressed prostatic secretions*.
- Prostate-specific antigen (PSA)
- age-specific, 115-116
  - density of, 115
  - discovery of, ix
  - finasteride and, 86, 97
  - LHRH analogues and, 132
  - molecular forms of (free and bound), 114-115
  - in prostate cancer, ix-x, 113-115, 146, 147-148
  - radiation therapy and, 126
  - velocity of, 115
- Prostatectomy. See also *Transurethral resection of prostate*.
- laser in, ix, 99-100, 101, 102
  - open, for BPH, 57-58
    - complications of, 106
    - indications for, 106
    - surgical techniques in, 106
  - radical, 125-126, 145, 147
  - urethro-vesical junction disease after, 126
- Prostatic abscess
- antimicrobials for, 35
  - catheterizations and, 35
  - conditions predisposing to, 35
  - in diabetes mellitus, 35
  - diagnosis of, 26
  - incision and drainage of, 35
  - transurethral resection for, 36
- Prostatic acid phosphatase (PAP)
- in BPH, 114, 143
  - in prostate cancer, 114, 121t, 146, 148
- Prostatic antibacterial factor, 14
- Prostatic calculi, 33, 36, 142
- Prostatic fossa, length of, 51
- Prostatic hyperplasia, benign. See *Benign prostatic hyperplasia*.
- Prostatitis
- acute bacterial, x, 15, 16t
  - diabetes with, 139, 141
  - diagnosis of, 17t, 18-19, 23, 26, 27, 28t, 29-30, 30-31
  - etiology of, 15, 17t, 34, 139, 145
  - history taking in, 231
  - in immunocompromised patient, 34
  - microscopic findings in, 28t, 33-34, 139
  - organisms causing, 17t, 18
  - physical examination in, 23, 26

Prostatitis, acute bacterial (*continued*)  
 prostate massage in, 18, 26  
 rectal examination in, 18, 23, 139, 141  
 symptoms of, 15, 16t-17t, 18, 26, 139  
 treatment of, 33-35, 141  
 asymptomatic inflammatory  
 causes of, 17t  
 classification of, x, 15  
 diagnosis of, 17t  
 expressed prostatic secretions in, 16t  
 infertility and, 21, 38  
 causes of, 17t  
 chronic bacterial, x, 15, 16t  
 ESP sampling in, 119  
 etiology of, 17t, 18, 142  
 microscopic findings in, 28t, 33, 142  
 NIH Symptom Index for, 23, 24t-25t  
 organisms causing, 17t  
 symptoms of, 16t-17t, 18-19, 142  
 treatment of, 33, 35-36, 142  
 classification of, x, 15, 16t, 19  
 diagnosis of, 16t-17t, 18-19  
 differential, 23, 26, 141  
 flow chart in, 140  
 history taking in, 23  
 microscopic examination in, 26, 28t, 29-31  
 physical examination in, 23, 26  
 epididymitis from, 26, 27  
 localizing infection in, 28t, 32  
 nonbacterial. See *Chronic pelvic pain syndrome, inflammatory*.  
 treatment of, 17t  
 $\alpha_1$ -adrenergic blockers in, 37  
 anti-inflammatory agents in, 37  
 anticholinergic agents in, 37  
 antimicrobial, 34, 37  
 biofeedback in, 37  
 calculi and, 33, 36, 142  
 dietary, 37  
 difficulties in, 33  
 flow chart in, 140  
 incision and drainage in, 35  
 intravenous, 33, 35  
 lifestyle modification in, 38  
 long-term, 36

Prostatitis, acute bacterial (*continued*)  
 prostatic resection in, 36  
 sitz baths in, 37, 142  
 urinary retention in, 48  
 Prostatodynia. See *Chronic pelvic pain syndrome, noninflammatory*.  
 Prostatron. See *Transurethral microwave thermotherapy*.  
 PSA. See *Prostate-specific antigen*.  
 Pumpkin seeds, 62t  
 Purple cone flower, 62t  
 Pyelography, intravenous, 52, 53  
 Pyelonephritis, 26  
*Pygeum africanum* (African plum), 59, 62t, 62-63  
 Race, prostate cancer and, 107  
 Radiation therapy  
 for prostate cancer, ix, 126-127, 137, 148  
 cryosurgery after, 128  
 PSA and, 126  
 Radioactive implantation, 127  
 Radiologic studies, 52, 53  
 Rectal examination  
 in BPH, 48-49, 54, 142, 144-145  
 distortion of, 113  
 in noninflammatory CPPS, 20  
 normal, finasteride and, 86  
 procedure in, 49  
 in prostate cancer, 85, 95, 117, 119  
 in prostatitis, 18, 23, 139, 141  
 repeat, 145  
 TURP indicated by, 144-145  
 Rectal fissures, in prostatitis, 26  
 Rectal infection, 15  
 Rectal sphincter tone, 49  
 5 $\alpha$ -Reductase inhibitors. See also specific drug, eg, *Finasteride*.  
 $\alpha$ -adrenergic blockers with, 95  
 African plum vs, 63  
 for BPH, ix, 57, 66t, 82-83, 95  
 dihydrotestosterone and, 67t, 82-83  
 molecular structures of, 65  
 prostate cancer and, 131  
 PSA and, 97  
 Renal colic, 23  
 Renal fissure, 26

Resection, prostatic. See *Transurethral resection of prostate*.

Rye extract, 62t

Saw palmetto, ix

action mechanism of, 59

for BPH, ix, 62t

finasteride vs, 59

scientific name of, 62t

urologic symptoms and flow rates after, 59

*Secale cereale* (rye), 62t

Sequential Multiple Analysis (SMA-6), 50

*Serenoa repens*. See *Saw palmetto*.

Serum markers, of prostate cancer, 114-116, 146, 147

Sexual activity, 37

Sitz bath, 37, 142

Sonography. See *Ultrasound*.

South African star grass, 62t

South African star grass extract, 62t

Spermatozoa, antibacterial, 14

Spermine, 46

Sphincter, rectal, tone of, 49

Spinal cord compression, 137

*Staphylococcus*, coagulase-negative, CPPS from, 21

Stenting, prostatic, 57, 97-98

Steroids, 137

Stinging nettle, 62t

Stones. See *Calculi*.

Stress, noninflammatory CPPS and, 21

Stress incontinence, 106

Strictures

of bladder neck, 102

urethral, 19, 48, 100, 106, 127

Strontium, 137

Sulfamethoxazole

for bacterial prostatitis

acute, 34, 141

chronic, 35, 37, 142

for noninflammatory CPPS, 37

Tamsulosin (Flomax)

action mechanism of, 66t

advantages of, 73, 76

for BPH, 57, 64

dosage of, 66t, 73, 78

Tamsulosin (*continued*)

doxazosin vs, 73

effectiveness of, 66t, 73, 74-75, 76, 77

for noninflammatory CPPS, 37

pharmacokinetics of, 66t, 73

safety of, 76

side effects of, 66t, 73, 76-77

structure of, 65

symptom score after-, 73, 75, 76, 77

terazosin vs, 73

urinary flow after, 74-75, 76, 77

Terazosin (Hytrin)

action mechanism of, 66t

blood pressure and, 69

for BPH, 57, 64, 65, 66t, 69-70

cholesterol and, 64

dosage of, 66t, 70

effectiveness of, 64, 69, 73, 100

finasteride vs, 69

for noninflammatory CPPS, 37

pharmacokinetics of, 64, 66t

side effects of, 64, 66t

structure of, 65

symptom score after, 68, 68

tamsulosin vs, 73

TUMT and TURP vs, 100

urinary flow after, 68

Terpenoids, from plant extracts, 62t

Testicular pain, in CPPS, 19

Testosterone, 40, 41, 42. See also *Dihydrotestosterone*.

saw palmetto effect on, 59

Tetracycline

for chronic bacterial prostatitis, 36

for CPPS

inflammatory, 36, 140

noninflammatory, 37, 141-142

for gonorrhea or chlamydial infection, 141

Thermotherapy, microwave. See *Transurethral microwave thermotherapy*.

TMP-SMX. See *Sulfamethoxazole*; *Trimethoprim*.

TNM (tumor, nodes, and metastases) classification of prostate cancer, 119, 120t-122t

Toxins, environmental, prostate cancer and, 108

Tranquilizers, 48

Transrectal ultrasound (TRUS)-guided biopsy, x, 116-117

- Transurethral incision of prostate (TUIP)  
 for BPH, 57, 102, 143  
 complications of, 103  
 indications for, 55, 102, 144-145  
 techniques in, 102-103, 103
- Transurethral microwave thermotherapy (TUMT), ix-x  
 action mechanisms of, 98  
 advantages of, 57  
 effect on  $\alpha$ -adrenergic tone of capsular smooth muscle, 98  
 effectiveness of, 99, 100, 144-145  
 frequency of, x  
 indications for, 55, 99, 143, 144-145  
 pressure-flow changes after, 99  
 terazosin vs, 100  
 TURP vs, 100
- Transurethral needle ablation of prostate (TUNA), 57  
 indications for, 55, 143, 144  
 procedures in, 102
- Transurethral resection of prostate (TURP)  
 for BPH, x, 37, 57, 100, 104-106, 105, 143, 144  
 for chronic bacterial prostatitis, 36  
 complications of, 105-106  
 contraindications for, 102, 144  
 cystoscopy before, 51  
 effectiveness of, 36, 99, 100, 106  
 indications for, 104  
 laser vs, 100, 102  
 outcome of, 106  
 for prostatic abscess, 36  
 techniques in, 104-105, 105
- Transurethral vaporization of prostate (TUVP), 57, 103-104
- Trials  
 CAMUS, 63  
 MTOPS, 95-97  
 PLESS, 84-85, 84-85  
 Prostate Cancer Prevention Trial, 86, 88-89
- Tricyclic antidepressants, 48
- Trimethoprim  
 for bacterial prostatitis  
 acute, 34, 141  
 chronic, 35, 37, 142  
 for noninflammatory CPPS, 37
- TRUS (transrectal ultrasound)-guided biopsy, x, 116-117
- TUIP. See *Transurethral incision of prostate*.
- Tumor(s)  
 in bladder, 48, 51  
 invasion by, in prostate cancer staging, 121t  
 metastasis of, in prostate cancer staging, 121t-122t  
 primary, in prostate cancer staging, 120t-121t
- TUMT. See *Transurethral microwave thermotherapy*.
- TUNA (transurethral needle ablation of prostate), 57  
 indications for, 55, 143, 144  
 procedures in, 102
- TURP. See *Transurethral resection of prostate*.
- TUVP (transurethral vaporization of prostate), 57, 103-104
- Ultrasound  
 in BPH  
 diagnostic, 52, 53  
 therapeutic, 57  
 transrectal  
 biopsy guided by, x, 116-117  
 in prostate cancer, x, 116-117, 128
- Ureaplasma* infection  
 asymptomatic inflammatory prostatitis from, 17t  
 inflammatory CPPS from, 17t
- Uremia, 104
- Urethra  
 in acute bacterial prostatitis, 15  
 cancer zones in, 109, 110  
 obstructed by enlarged/inflamed prostate, 11, 33, 41, 42  
 strictures of, 19, 48, 100, 106, 127
- Urethritis  
 chlamydial, 141  
 microscopic findings in, 28t  
 pain from, in CPPS, 19  
 symptoms of, 26
- Urethro-vesical junction disease, 126
- Urinary flow rate. See also *Benign prostatic hyperplasia*.  
 age and, 50  
 alfuzosin and, 79, 80-81  
 doxazosin and, 72  
 dutasteride and, 91-92, 93  
 finasteride and, 83  
 in prostatitis, 17t  
 in prostatitis syndromes, 17t  
 tamsulosin and, 74, 76, 77  
 terazosin and, 68  
 TUMT and, 99

- Urinary frequency/urgency
  - in acute bacterial prostatitis, 18
  - anticholinergic agents for, 37
  - causes of, 41, 47-48
  - in chronic bacterial prostatitis, 18, 142
  - drugs for, 63-64
  - in noninflammatory CPPS, 20
  - in prostate cancer, 113
  - saw palmetto and herbs for, x, 62t
- Urinary hesitancy, 48
- Urinary obstruction, 44, 51
- Urinary retention
  - age/aging and, ix
  - brachytherapy and, 127
  - causes of, 48
  - enlarged/inflamed prostate and, 33, 144-145
  - treatment of, 35
    - surgical, 58, 104-105
  - urinary tract infection from, 104
- Urinary tract, lower
  - BPH effects on, 39
  - refractory symptoms in
    - phytotherapy for, 58-59
    - surgery for, 58
- Urinary tract infection
  - catheter-induced, 145
  - chronic, 58, 142
  - cystitis and, 26
  - pain from, in CPPS, 19
  - prostatitis from, 17t, 18, 23
  - urinary frequency in, 47, 142
  - urinary retention and, 104
- Urine, blood in, 104
- Urine specimen
  - collection of, 26, 29, 30
  - to localize infection, 26, 31, 32
  - microscopic examination of
    - in BPH, 50
    - in prostatitis, 28t, 29-30, 30-31, 32
  - before and after prostatic massage, 31
- Urodynamic testing, 50-51, 145
- Uroflow test, 50
- Uroxatral. See *Alfuzosin*.
- Urtica dioica* (stinging nettle), 62t
- Vaccination, in hormone-refractory prostate cancer, 137
- Vaporization of prostate, 103-104
- Vasculature, of prostate, 11, 13
- Venous congestion, intrapelvic, 21
- Viadur (leuprolide acetate implant)
  - dosage of, 132
  - indications for, 148
  - side effects of, 133
- Viral infection
  - HIV as, 35
  - prostate cancer and, 108
- Visual laser ablation of prostate (VLAP), x, 57, 99-100, 101, 143
- Voided bladder, 26, 30
- Whitmore-Jewett prostate cancer stages, 119, 120t, 122t, 123
- Zinc, 46